The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance. A new analysis using CRISPR screens has revealed insights that ...

Approximately half of men with metastatic castration-resistant prostate cancer and BRCA1 or BRCA2 mutations do not receive medications that could improve their survival.Poly (adenosine ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

The use of PARP inhibitors for the treatment of patients with BRCA1/2 mutations represents a milestone in genomically-directed therapies. Olaparib and talazoparib have shown to significantly extend ...

ORLANDO, Fla. (Ivanhoe Newswire) - Almost 20,000 women developed ovarian cancer this year, and experts projected 12,000 women will die from it. For years, it’s been known as the silent killer because ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. It's really changed the way we think about ...

Credit: Getty Images Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests. Combining camonsertib with PARP inhibitors may be an ...

Rakovina Therapeutics Inc ( ($TSE:RKV) ) has shared an update. Rakovina Therapeutics Inc. presented a second scientific abstract at the 2025 ...

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy.

Researchers from The University of Texas MD Anderson Cancer Center identified a new role for heat shock protein 90 (HSP90) in ...